Literature DB >> 31605779

The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.

Noémie Cresto1, Marie-Claude Gaillard1, Camille Gardier1, Francesco Gubinelli1, Elsa Diguet2, Déborah Bellet1, Laurine Legroux1, Julien Mitja1, Gwenaëlle Auregan1, Martine Guillermier1, Charlène Josephine1, Caroline Jan1, Noëlle Dufour1, Alain Joliot3, Philippe Hantraye1, Gilles Bonvento1, Nicole Déglon4, Alexis-Pierre Bemelmans1, Karine Cambon1, Géraldine Liot1, Emmanuel Brouillet5.   

Abstract

The G2019S substitution in the kinase domain of LRRK2 (LRRK2G2019S) is the most prevalent mutation associated with Parkinson's disease (PD). Neurotoxic effects of LRRK2G2019S are thought to result from an increase in its kinase activity as compared to wild type LRRK2. However, it is unclear whether the kinase domain of LRRK2G2019S is sufficient to trigger degeneration or if the full length protein is required. To address this question, we generated constructs corresponding to the C-terminal domain of LRRK2LRRK2). A kinase activity that was increased by G2019➔S substitution could be detected in ΔLRRK2. However biochemical experiments suggested it did not bind or phosphorylate the substrate RAB10, in contrast to full length LRRK2. The overexpression of ΔLRRK2G2019S in the rat striatum using lentiviral vectors (LVs) offered a straightforward and simple way to investigate its effects in neurons in vivo. Results from a RT-qPCR array analysis indicated that ΔLRRK2G2019S led to significant mRNA expression changes consistent with a kinase-dependent mechanism. We next asked whether ΔLRRK2 could be sufficient to trigger neurodegeneration in the substantia nigra pars compacta (SNc) in adult rats. Six months after infection of the substantia nigra pars compacta (SNc) with LV-ΔLRRK2WT or LV-ΔLRRK2G2019S, the number of DA neurons was unchanged. To examine whether higher levels of ΔLRRK2G2019S could trigger degeneration we cloned ΔLRRK2 in AAV2/9 construct. As expected, AAV2/9 injected in the SNc led to neuronal expression of ΔLRRK2WT and ΔLRRK2G2019S at much higher levels than those obtained with LVs. Six months after injection, unbiased stereology showed that AAV-ΔLRRK2G2019S produced a significant ~30% loss of neurons positive for tyrosine hydroxylase- and for the vesicular dopamine transporter whereas AAV-ΔLRRK2WT did not. These findings show that overexpression of the C-terminal part of LRRK2 containing the mutant kinase domain is sufficient to trigger degeneration of DA neurons, through cell-autonomous mechanisms, possibly independent of RAB10.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  AAVs; Lentiviral vectors; Leucine-rich repeat kinase 2; Parkinson's disease

Mesh:

Substances:

Year:  2019        PMID: 31605779     DOI: 10.1016/j.nbd.2019.104614

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  6 in total

1.  Complete spatial characterisation of N-glycosylation upon striatal neuroinflammation in the rodent brain.

Authors:  Ana Lúcia Rebelo; Francesco Gubinelli; Pauline Roost; Caroline Jan; Emmanuel Brouillet; Nadja Van Camp; Richard R Drake; Radka Saldova; Abhay Pandit
Journal:  J Neuroinflammation       Date:  2021-05-16       Impact factor: 8.322

2.  LRRK2-G2019S mice display alterations in glutamatergic synaptic transmission in midbrain dopamine neurons.

Authors:  Olga Skiteva; Ning Yao; Giacomo Sitzia; Karima Chergui
Journal:  J Neurochem       Date:  2022-02-27       Impact factor: 5.546

3.  Genetically modified macrophages accelerate myelin repair.

Authors:  Marie-Stéphane Aigrot; Clara Barthelemy; Sarah Moyon; Gaelle Dufayet-Chaffaud; Leire Izagirre-Urizar; Beatrix Gillet-Legrand; Satoru Tada; Laura Bayón-Cordero; Juan-Carlos Chara; Carlos Matute; Nathalie Cartier; Catherine Lubetzki; Vanja Tepavčević
Journal:  EMBO Mol Med       Date:  2022-07-13       Impact factor: 14.260

Review 4.  Molecular Pathways Involved in LRRK2-Linked Parkinson's Disease: A Systematic Review.

Authors:  Ailyn Irvita Ravinther; Hemaniswarri Dewi Dewadas; Shi Ruo Tong; Chai Nien Foo; Yu-En Lin; Cheng-Ting Chien; Yang Mooi Lim
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

Review 5.  Adeno-Associated Viral Vectors as Versatile Tools for Parkinson's Research, Both for Disease Modeling Purposes and for Therapeutic Uses.

Authors:  Ana Fajardo-Serrano; Alberto J Rico; Elvira Roda; Adriana Honrubia; Sandra Arrieta; Goiaz Ariznabarreta; Julia Chocarro; Elena Lorenzo-Ramos; Alvaro Pejenaute; Alfonso Vázquez; José Luis Lanciego
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

6.  The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo.

Authors:  Noémie Cresto; Camille Gardier; Marie-Claude Gaillard; Francesco Gubinelli; Pauline Roost; Daniela Molina; Charlène Josephine; Noëlle Dufour; Gwenaëlle Auregan; Martine Guillermier; Suéva Bernier; Caroline Jan; Pauline Gipchtein; Philippe Hantraye; Marie-Christine Chartier-Harlin; Gilles Bonvento; Nadja Van Camp; Jean-Marc Taymans; Karine Cambon; Géraldine Liot; Alexis-Pierre Bemelmans; Emmanuel Brouillet
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.